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Effect of fasudil on Rho-kinase and nephropathy in subtotally
nephrectomized spontaneously hypertensive rats.
Background. Although Rho-kinase is reported to play an
important role in vascular injury, the contribution of Rho-kinase
to the progression of renal injury remains unestablished.
Methods. We examined the effect of fasudil, a Rho-kinase
inhibitor, on the progression of renal injury in subtotally
nephrectomized spontaneously hypertensive rats (SHR). Rats
were randomly assigned to three groups: sham-operated SHR;
salt-loaded subtotally nephrectomized rats (SHR-subtotal
nephrectomy); SHR-subtotal nephrectomy given fasudil for
6 weeks (SHR-subtotal nephrectomy + fasudil; 3 mg/kg/day).
Renal morphologic and molecular analysis as well as urinary
protein excretion was evaluated.
Results. In SHR-subtotal nephrectomy treated with fasudil,
systolic blood pressure was not significantly different from that
in SHR-subtotal nephrectomy without fasudil (208 ± 8 mm
Hg vs. 217 ± 14 mm Hg). Urinary protein excretion was
markedly increased in SHR-subtotal nephrectomy (124 ±
16 mg/day), but this increase was significantly suppressed by
fasudil (79 ± 12 mg/day). Renal histologic examination re-
vealed that fasudil improved glomerular and tubulointerstitial
injury scores with parallel amelioration of proliferating cell nu-
clear antigen-positive and ED-1–positive cell infiltration. Fur-
thermore, Western blot analyses showed that both expression
and activity of Rho-kinase were enhanced in SHR-subtotal
nephrectomy, compared with those in SHR without nephrec-
tomy, and fasudil suppressed Rho-kinase activity. Finally,
fasudil up-regulated the expression of p27kip1, a cyclin-
dependent kinase inhibitor, and increased the p27kip1
immunopositive cells in both glomeruli and tubulointerstitium
with the use of immunohistochemistry.
Conclusion. Rho-kinase pathway is involved in the patho-
genesis of renal injury. Furthermore, the inhibition of Rho-
kinase may constitute a therapeutic strategy for the treatment
of renal injury in part through the p27kip1 up-regulation and
the subsequent inhibition of cell proliferation and macrophage
recruitment.
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Small G protein Rho and its effector Rho-kinase
play an important role in various cellular functions [1].
Rho/Rho-kinase inhibits myosin phosphatase by phos-
phorylating its myosin-binding subunit (MBS), favoring
accumulation of phosphorylated myosin light chain and
enhanced contraction of vascular smooth muscle cell
(VSMC) [2]. Indeed, Uehata et al [3] have documented
that a novel Rho-kinase inhibitor, Y-27632, markedly
reduces blood pressure in three different forms of experi-
mental hypertensive animals, and suggest that Rho/Rho-
kinase participates importantly in the regulation of
systemic vascular tone. In addition to the hemodynamic
action, it has also been established that Rho/Rho-kinase
participates in cell adhesion/migration and proliferation
[4, 5], and is involved in various models of cardiovascular
disorders, independently of systemic blood pressure [6].
Thus, the inhibition of Rho-kinase is reported to suppress
the neointimal formation of balloon-injured rat carotid
arteries [7], and attenuate the formation of the coronary
injury induced by the chronic treatment with monocyte
chemoattractant protein-1 (MCP-1) and/or low-density
lipoprotein (LDL) [8]. Recently, a couple of studies
have examined the role of Rho-kinase in renal cells in
culture [9, 10]. Endlich et al [9] found that Y-27632
inhibited the reorganization of cytoskeleton induced by
mechanical stress in cultured renal podocytes. Further-
more, the inhibition of Rho-kinase activity is reported
to prevent the transforming growth factor-b (TGF-b)-
induced increase in connective tissue growth factor
accumulation in cultured human renal fibroblast cells
[10]. Although these in vitro observations strongly sug-
gest a substantial role of Rho-kinase in mediating the
progression of renal injury, direct in vivo evidence for the
contribution of Rho-kinase to the development of renal
disease is insufficient.
Multiple mechanisms have been suggested regarding
the role of Rho-kinase in the pathogenesis of various dis-
eases. Among them, activated Rho promotes the degra-
dation of a cyclin-dependent kinase inhibitor p27kip1
[11] and/or decreases translational efficiency of p27kip1
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mRNA [12] and enhances cell cycle progression, which
may contribute to the proliferative process of the vascu-
lar tissue. The amount of p27kip1 establishes a threshold
to which G1 cyclin-cyclin-dependent kinase complexes
must surpass prior to cells progressing into S phase.
Recent studies have demonstrated that up-regulation of
p27kip1 leads to the inhibition of proliferation in various
renal cells [13, 14]. Indeed, in renal diseases, p27kip1 safe-
guards against immune and nonimmune inflammatory
injury [15]. In concert, these observations lend support
to the premise that the expression of p27kip1 mediates the
Rho-kinase inhibitor-induced renal protection.
In the present study, we investigated the role of
Rho/Rho-kinase in the progression of renal injury
in subtotally nephrectomized spontaneously hyperten-
sive rats (SHR), with the use of a relatively specific
Rho-kinase inhibitor, fasudil [3]. This agent acquires
unique characteristics when administered in vivo; its
metabolite, hydroxy fasudil, still retains its activity and
possesses a more selective action than its parent drug
on Rho-kinase [16, 17]. Furthermore, the role of p27kip1
in the renal Rho-kinase–mediated process was also
examined. The animal model used in the present study
is unique in that hypertension continues to develop
early from the beginning of salt loading and is therefore
suited for investigation of accelerated hypertension with
renal insufficiency [18]. The present study demonstrates
that renal injury is associated with the up-regulation of
Rho-kinase. Furthermore, the Rho-kinase inhibition by a
subdepressor dose of fasudil ameliorated proteinuria and
renal morphologic damage. Finally, the treatment with
fasudil up-regulated the expression of p27kip1 in renal tis-
sues, which may contribute to its renal protective action
in this model of renal injury.
METHODS
Animal experimental protocols
Six-week-old male SHR (N = 26) (Charles River
Japan, Kanagawa, Japan) weighing 130 to 140 g were
used. They were placed in individual metabolic cages
and were initially fed with a standard rat chow
(15 g/day, 0.38% sodium, 0.97% potassium, and 25.1%
protein) (Nippon Clea, Tokyo, Japan) and given water ad
libitum. Rats were randomly assigned to three groups:
group 1, sham-operated rats (SHR, N = 10); group 2,
subtotally nephrectomized rats (SHR-subtotal nephrec-
tomy, N = 8); and group 3, SHR-subtotal nephrectomized
rats given fasudil (SHR-subtotal nephrectomy + fasudil,
N = 8; 3 mg/kg/day, intraperitoneally) (Asahi Kasei,
Tokyo, Japan). In our preliminary study, we examined
acute effects of intraperitoneal administration of fasudil
on systolic blood pressure (measured by tail-cuff method)
(KN-210, Natsume, Tokyo, Japan) in 8-week old SHR and
found that fasudil at a dose of 10 mg/kg decreased sys-
tolic blood pressure (change at 1 hour, −25 ± 2 mm Hg;
at 3 hours −11 ± 1 mm Hg, N = 5), but had no effect on
systolic blood pressure at 3 mg/kg (at 1 hour, −5 ± 2 mm
Hg; at 3 hours 1 ± 3 mm Hg, N = 5). Because the aim of
our current study was to clarify the role of Rho-kinase in
mediating the renal injury, we adopted 3 mg/kg/day as a
subdepressor dose of fasudil.
Subtotal nephrectomy was performed by removal of
two thirds of the left kidney (week 0), followed by total
right nephrectomy (week 1) under ether anesthesia [18].
Thereafter, the standard chow was switched to a high salt
chow (5% NaCl, 15 g/day) for SHR-subtotal nephrec-
tomy and SHR-subtotal nephrectomy + fasudil, and the
treatment with fasudil started at week 2. Body weight,
systolic blood pressure and 24-hour urinary protein
excretion were evaluated every 2 weeks throughout the
study. At week 8, rats in each group were decapitated and
blood was collected. All experiments were performed in
accordance with the animal experimentation guideline of
Keio University School of Medicine.
Morphologic examination
Kidneys were fixed in 10% formaldehyde and then em-
bedded in paraffin blocks. Histologic sections from the
rat kidneys were stained with periodic acid-Schiff (PAS)
stain, and histologic examination was performed semi-
quantitatively on five independent rat kidneys in each
group [19]. Fifty glomeruli, all the observed sections of
blood vessels, and 20 cortical fields without any glomeru-
lus were evaluated on an individual rat by two inves-
tigators in a blinded fashion. The number of glomeruli
exhibiting focal or global ischemic or proliferative dam-
age was enumerated and expressed as a percentage of
the total number of glomeruli examined. Blood vessels
were graded 0 to 4 for arteriolar sclerosis, on the basis
of the severity of hyalinosis and thickening of the vas-
cular wall. Tubulointerstitial changes, including intersti-
tial inflammation and tubular atrophy, were assessed and
graded 0 to 3, as follows: grade 1, involvement of <20%
of the cortical interstitium; grade 2, involvement of 20%
to 40% of the interstitium; and grade 3, involvement of
>40% of the interstitium [19]. Mean glomerular tuft vol-
ume (GV) was determined from the mean glomerular
cross-sectional area by light microscopy as described pre-
viously [20]. The results are expressed as fold increases
from the GV in the SHR kidney.
Immunohistochemistry
Tissue samples were fixed using 10% formaldehyde.
Histologic samples were embedded in paraffin and
4 lm sections were used for immunohistochemical
analysis. After the quenching of the endogenous per-
oxidase activity, sections were incubated with the pri-
mary antibody against proliferating cell nuclear antigen
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(PCNA) (Pharmingen, San Diego, CA, USA) at
1:1000 dilutions, p27kip1 (Transduction Laboratories,
Lexington, MA, USA) at 1:200 and ED-1 (BMA Biomed-
icals, Augst, Switzerland) at 1:2000 for 1 hour at room
temperature. The slides were incubated with appropriate
secondary antibodies for 30 minutes. The sections were
rinsed in phosphate-buffered saline (PBS), and incubated
in 0.02% 3, 3′-diaminobenzidine tetrahydrochloride. The
sections were slightly counterstained with Mayer’s hema-
toxylin. Negative controls were obtained by replacing
specific antisera with nonimmune sera, and no significant
staining was observed in the negative controls.
Quantification of nuclear staining for PCNA, p27kip1
and ED-1 was performed in 30 consecutive glomeru-
lar cross-sections and 20 high-power (i.e., ×400) fields
of tubulointerstitium without any glomerulus from five
independent rat kidneys in each group. PCNA-positive,
p27kip1-positive and ED-1–positive cells were counted
by computer-aided planimetry using the Scion Image
software (Scion Corp., Fredrick, MD, USA). In detail,
images were digitized and captured with a charged cou-
pling device (CCD) camera connected to a personal
computer, and scanned into Photoshop (Adobe Sys-
tems, San Jose, CA, USA). A binary overlay was created
automatically, and the threshold of the binary overlays
was adjusted by comparing image to optimal match of
each spot. The value of the threshold setting was kept
constant.
Western blot analysis
Portions of renal cortex were excised and snap
frozen. Renal cortical tissues were lysed and sonicated
in solubilization buffer [21]. Immunoblot analysis was
performed as previously described [21], with some
modifications. Blots were incubated with specific anti-
bodies against Rho-kinase (ROCa; Transduction Labo-
ratories), p27kip1, p21cip1 (Santa Cruz Biochemical, Santa
Cruz, CA, USA) at a 1:200 concentration. Rho-kinase
activity was determined by evaluating the phosphory-
lated MBS (also known as a myosin phosphatase target
subunit, MYPT) with an antibody that specifically rec-
ognized MBS phosphorylation at Ser-854 by Rho-kinase
(a gift from K Kaibuchi, Nagoya University, Nagoya,
Japan) [22].
Statistical analysis
Data are expressed as mean ± SEM. Data were
analyzed by two-way analysis of variance (ANOVA),
followed by Bonferroni’s multiple comparison post hoc
test. Histologic results were analyzed by Kruskal-Wallis
nonparametric test. P < 0.05 was considered statistically
significant.
RESULTS
Body weight after 8 weeks of subtotal nephrectomy
(169 ± 7 g, N = 8) was significantly less than that in sham-
operated SHR (253 ± 3 g, N = 10, P < 0.01). The treat-
ment with fasudil, however, had no effect on the changes
in body weight; at 8 weeks, the body weight was 174 ±
10 g in SHR-subtotal nephrectomy + fasudil (N = 8,
P > 0.5 vs. SHR-subtotal nephrectomy). Serum levels of
albumin did not differ among three groups (SHR, 3.9 ±
0.2 g/dL; SHR-subtotal nephrectomy, 3.4 ± 0.1 g/dL;
SHR-subtotal nephrectomy + fasudil, 3.6 ± 0.2 g/dL).
The serum creatinine level was significantly higher in
SHR-subtotal nephrectomy (0.72 ± 0.14 mg/dL) than
in SHR (0.33 ± 0.02 mg/dL, P < 0.01), and the 6-week
treatment with fasudil did not affect the serum creati-
nine level (SHR-subtotal nephrectomy + fasudil, 0.60 ±
0.09 mg/dL, P > 0.4 vs. SHR-subtotal nephrectomy).
Effect of fasudil on blood pressure and proteinuria
Systolic blood pressure in both SHR-subtotal nephrec-
tomy (N = 8) and fasudil-treated SHR-subtotal nephrec-
tomy groups (N = 8) was elevated markedly compared
with SHR (N = 10). After subtotal nephrectomy and high
salt diet loading, systolic blood pressure increased from
149 ± 3 mm Hg (at 2 weeks) to 217 ± 14 mm Hg
(at 8 weeks) in SHR-subtotal nephrectomy group.
Although systolic blood pressure in fasudil-treated SHR-
subtotal nephrectomy (e.g., 208 ± 8 mm Hg at 8 weeks)
tended to be lower than that in SHR-subtotal nephrec-
tomy, this difference did not attain statistical significance
(P > 0.1).
Subtotal nephrectomy induced proteinuria at 2 weeks
(SHR, 6 ± 1 mg/day, N = 10; SHR-subtotal nephrectomy,
21 ± 1 mg/day, N = 8; P < 0.01 vs. SHR), and further
increases in proteinuria were observed, attaining 124 ±
16 mg/day at 8 weeks (P < 0.01 vs. SHR) (Fig. 1). In con-
trast, the treatment with fasudil significantly attenuated
the increases in proteinuria. Thus, urinary protein excre-
tion was less at 4 weeks (26 ± 3 vs. 41 ± 6 mg/day, P < 0.05
vs. SHR-subtotal nephrectomy, N = 8), and this benefi-
cial effect persisted throughout the experimental period
(6 weeks, 46 ± 8 mg/day; 8 weeks, 79 ± 12 mg/day).
Effect of fasudil on renal morphologic changes
The renal histologic preparation of the sham-operated
SHR showed only slight arteriolosclerosis and glomeru-
lar/tubulointerstitial changes (Fig. 2A). As illustrated in
Figure 2B, subtotal nephrectomy produced prominent
thickening of arterioles, as well as proliferative damage
of glomerular, interstitial inflammation and tubular atro-
phy. These changes were improved by the treatment with
fasudil (Fig. 2C). When the effect of fasudil is sum-
marized, it is evident that the treatment with fasudil
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Fig. 1. Changes in urinary protein excretion in spontaneously hyper-
tensive rats (SHR), subtotally nephrectomized SHR (SHR-subtotal
nephrectomy), and fasudil-treated SHR-subtotal nephrectomy. Uri-
nary protein excretion (mg/24 hours) was increased following subtotal
nephrectomy and high salt diet loading. This increase was significantly
suppressed by the treatment with fasudil. Symbols are: () SHR (N =
10); (), SHR-subtotal nephrectomy (N = 8); (), fasudil-treated SHR-
subtotal nephrectomy (N = 8). Values are mean ± SEM. ∗P < 0.05 vs.
SHR; ∗∗P < 0.01 vs. SHR; †P < 0.05 vs. SHR-subtotal nephrectomy.
ameliorates the renal injury induced by subtotal nephrec-
tomy; both glomerular and vascular scores were signifi-
cantly reduced (Fig. 2D). Furthermore, fasudil markedly
reduced tubulointerstitial scores from 1.7 ± 0.3 to 0.8 ±
0.2 (P < 0.05 vs. SHR-subtotal nephrectomy, N = 5).
GV in SHR-subtotal nephrectomy was markedly in-
creased, compared with that in SHR (SHR-subtotal
nephrectomy, 2.95 ± 0.10-fold increase, P < 0.01, N = 5).
The treatment with fasudil tended to reduce GV (SHR-
subtotal nephrectomy+ fasudil, 2.61±0.19, fold increase,
N = 5), although the change did not attain statistical sig-
nificance (P > 0.1 vs. SHR-subtotal nephrectomy).
Effect of fasudil on cell proliferation
The effect of the treatment with fasudil on cell pro-
liferation was investigated (Fig. 3). Immunostaining for
PCNA was negligible in the glomerulus and tubuloin-
terstitium of SHR kidneys (Fig. 3A). In SHR-subtotal
nephrectomy rats, PCNA-positive cells were present in
glomeruli and tubulointerstitium (Fig. 3B). The treat-
ment with fasudil, however, reduced the number of
PCNA-positive cells in both glomeruli and tubulointer-
stitium (Fig. 3C). When the results are summarized, the
treatment with fasudil significantly decreases the PCNA
number in glomeruli (Fig. 3D) and tubulointerstitium
(Fig. 3E).
Effect of fasudil on Rho-kinase and MBS
phosphorylation expression
In order to explore the molecular mechanism by which
the treatment with fasudil ameliorated the renal damage
in SHR-subtotal nephrectomy, we first assessed the effect
of fasudil on the expression of Rho-kinase. Rho-kinase
protein expression was up-regulated in the SHR-subtotal
nephrectomy group compared with SHR, whereas fasudil
did not affect this up-regulation of Rho-kinase (N = 5)
(Fig. 4A).
Next, the activity of Rho-kinase in the kidney was eval-
uated using antibody against phosphorylated MBS. MBS
is one of the major substrates for Rho-kinase, and its
phosphorylation is generally acknowledged as a marker
for Rho-kinase activity in various tissues including vascu-
lature [7] and cardiac tissue [23]. MBS phosphorylation
was increased in the SHR-subtotal nephrectomy group
(N = 5) compared with SHR (N = 5), indicating the
augmentation of Rho-kinase activity in nephrectomized
kidney tissues. The increased MBS phosphorylation in
SHR-subtotal nephrectomy group was substantially sup-
pressed by fasudil (2.6 ± 0.2 vs. 1.8 ± 0.2-fold increase
from SHR, P < 0.05, N = 5), confirming potent inhibitory
action of fasudil in our preparation (Fig. 4B).
Effect of fasudil on p27kip1 and p21cip1 protein expression
p27kip1 protein expression was markedly increased in
the SHR-subtotal nephrectomy group (N = 5) compared
with SHR (N = 5) (Fig. 5A). Moreover, 6-week treat-
ment with fasudil elicited additional elevation in p27kip1
(N = 5). In contrast, another major cyclin-dependent
kinase (CDK) inhibitor, p21cip1 expression tended to de-
crease with the fasudil treatment in the remnant kidney
(Fig. 5B).
We further conducted immunohistochemical analysis
for quantification and localization of p27kip1-positive cells
within the kidney. In SHR-subtotal nephrectomy rats, the
number of p27kip1-positive cells was up-regulated in both
glomeruli and tubulointerstitium compared with SHR
(N = 5) (Fig. 6). The treatment with fasudil increased sig-
nificantly the number of p27kip1-positive cells compared
with SHR-subtotal nephrectomy (glomerulus, 51 ± 4 cells
vs. 38 ± 2 cells, P < 0.05; tubulointerstitium, 48 ± 2 cells
vs. 39 ± 3 cells, P < 0.05, N = 5), findings consistent with
the results of immunoblotting. Because of technical dif-
ficulty in double-immunostaining nuclear proteins such
as p27kip1 and PCNA on the same slice, we evaluated the
distribution patterns of p27kip1- and PCNA-positive cells
and the interplay of these cells on consecutive kidney sec-
tions. Thus, p27kip1 expression was commonly observed in
the region of renal injury not undergoing proliferation,
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Fig. 2. Morphological alterations in kidneys from spontaneously hypertensive rats (SHR) (A), subtotally nephrectomized SHR (SHR-subtotal
nephrectomy) (B), and fasudil-treated SHR-subtotal nephrectomy (C). Minor abnormalities of glomeruli, tubulointerstitium, and arterioles were
observed in SHR (A) [periodic acid-Schiff (PAS) stain, original magnification, ×200]. Marked arteriolosclerosis (open arrow) and glomerular
(closed small arrow)/tubulointerstitial (closed big arrow) changes were observed in SHR-subtotal nephrectomy (B). These morphologic changes
were attenuated by the administration of fasudil (C). The comparison among these groups indicates significant improvement by the treatment with
fasudil (D). Symbols are: ( ) SHR; () SHR-subtotal nephrectomy; (), SHR-subtotal nephrectomy + fasudil. Each bar represents the mean ±
SEM (N = 5). ∗∗P < 0.01 vs. SHR; †P < 0.05 vs. SHR-subtotal nephrectomy.
and was absent within proliferating tubulointerstitial cells
(Fig. 7).
Effect of fasudil on ED-1–positive cells
Subtotal nephrectomy caused marked infiltration of
ED-1–positive macrophages (Fig. 8B). At 8 weeks,
macrophages were present in both glomeruli and intersti-
tium. The treatment with fasudil significantly suppressed
the macrophage infiltration (glomerulus, 116 ± 14 cells
vs. 65 ± 15 cells, P < 0.05; interstitium, 27 ± 2 cells vs.
18 ± 2 cells, P < 0.05, N = 5).
DISCUSSION
In the present study, we have demonstrated that
fasudil, a novel Rho-kinase inhibitor, exerts renal favor-
able action in the hypertensive remnant kidney model.
Thus, the treatment with fasudil suppresses the increase
in urinary protein excretion observed in SHR-subtotal
nephrectomy (Fig. 1). Consistently, the 6-week treatment
with this agent inhibits glomerular and tubulointerstitial
changes (Fig. 2) as well as cellular proliferation (Fig. 3),
although we fail to demonstrate a significant improve-
ment in serum creatinine levels by fasudil. To the extent
that serum creatinine levels do not necessarily represent
a sensitive marker for renal function, available evidence
obtained from this study suggests a close relationship
between Rho-kinase and the renal injury. Indeed, the
Western blot analysis shows that both the protein
level and the activity of Rho-kinase are elevated in
SHR-subtotal nephrectomy, and the treatment with
fasudil inhibits the activity of Rho-kinase in the
kidney (Fig. 4). Taken together, these paralleled changes
in pathophysiologic (i.e., proteinuria and morphology)
and molecular parameters (i.e., Rho-kinase activity)
induced by the treatment with fasudil suggest that an
enhanced Rho-kinase activity is associated with the
aggravation of progressive renal disease.
Pharmacologic characteristics of fasudil and its util-
ity in vivo merit comment. Fasudil has a relatively
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Fig. 3. Immunostaining for proliferating cell nuclear antigen (PCNA) in kidneys from spontaneously hypertensive rats (SHR), subtotally nephrec-
tomized SHR (SHR-subtotal nephrectomy), and fasudil-treated SHR-subtotal nephrectomy. Immunostaining for PCNA was negligible in the
glomerulus and tubulointerstitium of SHR kidneys (A) (×200 magnification). Numerous PCNA-positive cells were observed in kidneys from SHR-
subtotal nephrectomy (B) (×200 magnification), whereas the treatment with fasudil markedly reduced the PCNA-positive cells in glomeruli and
tubulointerstitium (C) (×200 magnification). Symbols are: ( ) SHR; () SHR-subtotal nephrectomy; () SHR-subtotal nephrectomy + fasudil.
Each bar represents the mean ± SEM (N = 5). ∗∗P < 0.01 vs. SHR; †P < 0.05 vs. SHR-subtotal nephrectomy.
Fig. 4. Expression and function of Rho-
kinase in renal cortex of spontaneously
hypertensive rats (SHR), subtotally nephrec-
tomized SHR (SHR-subtotal nephrectomy),
and fasudil-treated SHR-subtotal nephrec-
tomy. Representative results of Western blots
for Rho-kinase expression (A) and phospho-
rylated myosin binding subunit (MBS) in
renal cortex (B) are illustrated on the top. The
results on densitometry for immunoblots are
expressed as fold induction of SHR kidney
(bottom). Each bar represents the mean ±
SEM from five animals in each group. Each
blot is representative of five independent
observations. ∗∗P < 0.01 vs. SHR; †P < 0.05
vs. SHR-subtotal nephrectomy.
specific inhibitory action on Rho-kinase [inhibition con-
stant 50 (IC50), 0.33 lmol], with less potent activity on
other kinases (e.g., 9.3 lmol and 55 lmol for IC50 for pro-
tein kinase C and myosin light chain kinase, respectively
[3]). When administered in vivo, fasudil is mainly metab-
olized to its active form, hydroxy fasudil, which inhibits
Rho-kinase with similar activity to fasudil (IC50, 0.9 to
1.8 lmol) but exerts much less (at least 100-fold)
inhibitory action on protein kinase C or myosin
light chain kinase [16] and manifests more sustained
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Fig. 5. Western blot for p27kip1 (A) and
p21cip1 (B) in renal cortex of spontaneously
hypertensive rats (SHR), subtotally nephrec-
tomized SHR (SHR-subtotal nephrectomy),
and fasudil-treated SHR-subtotal nephrec-
tomy. p27kip1 level was upregulated in SHR-
subtotal nephrectomy, and the treatment with
fasudil produced further elevation in this
expression. In contrast, p21cip1 expression
tended to decrease with the fasudil treatment.
Each bar represents the mean ± SEM from
five animals in each group. Each blot is rep-
resentative of five independent observations.
∗P < 0.05 vs. SHR; ∗∗P < 0.01 vs. SHR; †P <
0.05 vs. SHR-subtotal nephrectomy.
activity than fasudil (twofold) [17]. Of note, since hy-
droxy fasudil is mainly excreted by the kidney [24], this
compound may dominate in vivo and might thus con-
tribute more greatly to the inhibitory action on Rho-
kinase than its parent form in renal dysfunction. Caveat
is in order, however, since the accumulative property
of hydroxy fasudil may narrow optimal dose range of
fasudil when used in renal disease. Therefore, the de-
termination of the optimal dosage of fasudil for the
treatment of progressive renal disease warrants further
investigation.
Several lines of studies provide substantial evidence
that multiple factors contribute to the development of
chronic renal injury. For example, systemic hypertension
and the subsequent mechanical stress have been shown
to constitute precipitating factors mediating the deteri-
oration of renal injury [25]. Furthermore, angiotensin II
is established to be responsible at least in part for the
renal impairment in chronic renal disease, even though
systemic blood pressure is unaltered [26]. The latter
observation is consistent with previous reports that
non-hemodynamic actions of angiotensin II may be an
aggravating factor [27]. In this regard, it has been demon-
strated that angiotensin II [28] and mechanical stretch
[29] activate Rho-kinase in VSMCs. Moreover, enhanced
Rho-kinase activity is involved in the pathogenesis of
neointimal formation [7], which would subsequently lead
to the restenosis of vascular lumen. It can be extrapo-
lated therefore that the role of Rho-kinase is exaggerated
in pathophysiologic conditions, such as chronic renal in-
jury. In subtotal nephrectomy, alterations in glomerular
capillary pressure [30] may also play a role in the en-
hancement of Rho/Rho-kinase activity through the me-
chanical stretch [29]. Of note, although our current study
fails to demonstrate a significant reduction in systemic
blood pressure by a low dose of fasudil, even a modest
decrease in pressure loading could potentiate the ben-
eficial action of fasudil on renal injury. Obviously, a
substantial reduction of blood pressure with fasudil
would decrease proteinuria as well as glomerular injury
[31].
In contrast to substantial evidence for contribution of
Rho-kinase to cardiovascular disorders, little is known as
to the role of Rho-kinase in renal injury. In a study using
renal podocytes in culture, it has been demonstrated that
mechanical stress–induced reorganization of cytoskele-
ton is inhibited by Y-27632 [9]. Furthermore, Y-27632
and fasudil have recently been shown to prevent tubu-
lointerstitial fibrosis in the model of unilateral ureteral
obstruction [32, 33]. Nevertheless, these in vitro and in
vivo studies, with a relatively short time period, may
not necessarily reflect the progressive nature of chronic
renal disease. The present in vivo study documenting
a favorable effect of fasudil, a Rho-kinase inhibitor,
on the chronic progressive renal damage lends sup-
port to the recent observations described above. In this
regard, a couple of reports demonstrated that the treat-
ment with statins, which possess inhibitory action on
Rho/Rho-kinase pathway as well, improved various
renal injury models, including the remnant kidney [34]
and the glomerulonephritis [35].
It has been established that renal cell proliferation and
matrix expansion constitute one of the important factors
contributing to the development of glomerulosclerosis
and tubulointerstitial fibrosis [36, 37]. In the rat remnant
kidney model, renal cell proliferation has been demon-
strated widely in tubulointerstitium as well as glomeru-
lar areas, and prevention of these alterations parallels
the renal morphologic changes [38, 39]. In accordance
with these findings, we demonstrated that the treatment
of SHR-subtotal nephrectomy with fasudil resulted in a
reduced PCNA-positive cells in both the glomerulus and
the tubulointerstitium (Fig. 3), which presumably con-
tributed not only to the decrease in proteinuria but also
to the amelioration of morphologic changes. Collectively,
it is reasonable to speculate that the improvement of
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Fig. 6. Immunostaining for p27kip1 in
kidneys from spontaneously hypertensive
rats (SHR), subtotally nephrectomized SHR
(SHR-subtotal nephrectomy), and fasudil-
treated SHR-subtotal nephrectomy. Some
cells in the glomerulus and tubulointerstitium
of SHR kidneys were stained positive for
p27kip1 (A) (×200 magnification). Numerous
p27kip1-positive cells were observed in
kidneys from SHR-subtotal nephrectomy (B)
(×200 magnification), whereas the treatment
with fasudil significantly increased the
p27kip1-positive cells in glomeruli and
tubulointerstitium (C) (×200 magnification).
Symbols are: Symbols are: ( ) SHR; ()
SHR-subtotal nephrectomy; () SHR-
subtotal nephrectomy + fasudil. Each bar
represents the mean ± SEM (N = 5). ∗P <
0.05 vs. SHR; ∗∗P < 0.01 vs. SHR; †P < 0.05
vs. SHR-subtotal nephrectomy.
Fig. 7. Immunostaining for proliferating cell
nuclear antigen (PCNA) and p27kip1 on
the consecutive section. Renal cortex sec-
tions from subtotally nephrectomized SHR
are shown (×200 magnification). Note that
PCNA-immunoreactive areas (closed arrow)
within the lesion correspond generally to
p27kip1-poor regions (open arrow).
Fig. 8. Immunostaining for ED-1 in kid-
neys from spontaneously hypertensive rats
(SHR), subtotally nephrectomized SHR
(SHR-subtotal nephrectomy), and fasudil-
treated SHR-subtotal nephrectomy. Few
ED-1–positive cells were observed in the
glomerulus and tubulointerstitium of SHR
kidneys (A) (×200 magnification). How-
ever, there was a significant increase in
the number of ED-1–positive cells in kid-
neys from SHR-subtotal nephrectomy (B)
(×200 magnification), whereas the treatment
with fasudil markedly reduced the ED-1–
positive cells in glomeruli and interstitium (C)
(×200 magnification). Symbols are: ( ) SHR;
() SHR-subtotal nephrectomy; () SHR-
subtotal nephrectomy + fasudil. Each bar rep-
resents the mean ± SEM (N = 5). ∗P < 0.05
vs. SHR; ∗∗P < 0.01 vs. SHR; †P < 0.05 vs.
SHR-subtotal nephrectomy.
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renal damage is closely associated with the magnitude
of cell proliferation despite diverse methods used for the
treatment of renal injury. Of note, it has recently been
reported [abstract; Moriyama et al J Am Soc Nephrol
12:687A, 2001] in a preliminary study that fasudil sup-
presses DNA synthesis in mesangial cells, a finding in
agreement with our current observation. In contrast, their
group also demonstrated that Y-27632 failed to exert
inhibitory action on mouse renal fibroblast proliferation
[32]. These differences may depend on the types of cells
examined, or could be attributed to different disease
processes.
Cell growth is coordinated by the cell cycle progression,
which is regulated by the balance between the levels and
activities of cyclin, CDK, and CDK inhibitors. It has also
been addressed that Rho/Rho-kinase pathway shares the
action on cell growth by promoting cell cycle progres-
sion possibly through destabilizing p27kip1 [11] and/or
by decreasing translational efficiency of p27kip1 mRNA
[12]. Thus, direct inhibition of Rho/Rho-kinase path-
way by Clostridium botulinum C3 transferase or Y27632
increased p27kip1 expression, and inhibited the prolifer-
ation in various cells [7, 11]. In the present study, we
found that p27kip1 protein was markedly increased by
subtotal nephrectomy and further up-regulated by the
fasudil treatment (Figs. 5A and 6C). Of interest, p27kip1
is demonstrated to be elevated in a variety of renal
injury, including subtotal nephrectomy [39] and unilat-
eral ureteral obstruction [40], as well as in balloon-injured
arteries [41]. Since the overexpression of p27kip1 blunts
the neointimal thickening [41], and conversely p27kip1
gene knockout is associated with excessive cell prolifer-
ation and aggravation of glomerular or tubulointerstitial
injury after induction of glomerulonephritis and ureteral
obstruction [15], the beneficial role of p27kip1 is expected
to act teleologically to counter abnormal cell growth in
renal injury. Indeed, our finding that the PCNA positive
cells associated with low level of expression of p27kip1-
and p27kip1-positive cells are not associated with cell pro-
liferation (Fig. 7), agrees with the previous report [40],
although the technical difficulty in the double immunos-
taining on the same slice hampers the direct demon-
stration of the interaction between PCNA and p27kip1.
Furthermore, our observation that the treatment with
fasudil produces augmentation of p27kip1 levels and
reduction of cell proliferation (Figs. 3C, 5A, and 6C) coin-
cides with a recent report by Sawada et al [7] showing that
Rho-kinase inhibition by Y-27632 increases p27kip1 in
balloon-injured carotid arteries and supports the premise
that up-regulation of p27kip1 confers a favorable effect
on proliferative disease process. Although the possibility
that modest (but not significant) hypotensive action of
fasudil modifies renal p27kip1 expression cannot be elimi-
nated entirely, a recent report that antihypertensive drugs
such as angiotensin-converting enzyme (ACE) inhibitors
and triple therapy fail to influence p27kip1 expression
despite a reduction in blood pressure [40] rather favor
a blood pressure-independent action of fasudil on renal
p27kip1 up-regulation, which would contribute in part to
renal protection.
In analogy with the effect on p27kip1 expression,
the present study shows that subtotal nephrectomy
up-regulates p21cip1 expression [39]. Furthermore, the
fasudil treatment tends to decrease p21cip1 expression
(Fig. 5B), suggesting a possible link between Rho-kinase
and p21cip1. Although this observation appears intrigu-
ing, there also are reported divergent results showing that
Rho/Rho-kinase pathway down-regulates [42] or has no
effect on p21cip1 [7, 43]. The precise mechanism of action
of the fasudil treatment on p21cip1 expression therefore
requires further study.
In the present study, we further examined the ef-
fect of fasudil on macrophage infiltration within the
kidney. Thus, subtotal nephrectomy markedly enhanced
the ED-1–positive macrophage infiltration (Fig. 8B), a
finding in agree with the observation by Taal et al [44]
demonstrating an important role of macrophage infil-
tration in mediating the development of renal injury in
the remnant kidney model. More importantly, the inhi-
bition of Rho-kinase by fasudil substantially suppressed
the microphage infiltration (Fig. 8C). These findings
provide strong evidence for substantial participation of
Rho-kinase in the macrophage infiltration in the rem-
nant kidney model and are consistent with previous find-
ings by Nagatoya et al [32] and Satoh et al [33] obtained
in the unilateral ureteral obstruction model. Therefore,
the treatment with fasudil may ameliorate the renal
damage through its inhibitory effect on migration and
proliferation of macrophage.
Although the present study clearly demonstrates a pro-
tective role of fasudil in renal injury, additional pos-
sible mechanisms could contribute to the ameliorating
action of this agent. Recent studies demonstrate that
Rho-kinase inhibition by Y-27632 and fasudil dilates af-
ferent as well as efferent arterioles in the in vitro [45]
and in vivo hydronephrotic kidney models [46], although
the vasodilator response of efferent arterioles is slightly
less than that of afferent arterioles. These alterations in
renal microvascular tone may affect glomerular hemody-
namics [47] and subsequently the glomerular volume, and
could modify renal Rho-kinase activity [29] and proba-
bly p27kip1 expression through the decrease in mechani-
cal stress. Alternatively, a Rho-kinase inhibitor has been
shown to down-regulate the expression of proinflam-
matory substances, including MCP-1 and TGF-b1 [23],
which manifest enhanced activity in the remnant kidney
model [44]. These mechanisms of the Rho-kinase inhi-
bition may serve in part to exert renal protective action
in chronic renal injury. This surmise, however, requires
further investigations.
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CONCLUSION
The data in the present study provide strong evi-
dence for increased renal Rho-kinase expression and
activity in subtotally nephrectomized SHR that manifests
marked proteinuria and renal morphologic changes. Fur-
thermore, p27kip1 expression is pronouncedly increased
in the remnant kidney, suggesting a renal protective
action of p27kip1 to countervail the progression of renal
injury. Finally, the manipulation of Rho-kinase activity by
the fasudil treatment potently improves the renal dam-
age induced by subtotal nephrectomy. The inhibition of
Rho-kinase may therefore constitute a potential thera-
peutic tool for the treatment of renal disease.
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